公开(公告)号：US20210228584A1

公开(公告)日：2021-07-29

申请号：US17175252

申请日：2021-02-12

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Brian D. Frenzel ,  Philip Liaw

IPC: A61K31/519 ,  A61K45/06 ,  A61K9/00 ,  A61P39/00

Abstract: Methods for improving the therapeutic effectiveness of uridine administered to prevent and/or reduce various maladies including adverse event from drugs are provided. Aspects of the methods include administering an effective amount of a uridine maximizing adjuvant, e.g., a 2,2′-anhydropyrimidine, or a derivative thereof, to the subject. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including the treatment of a variety of different disease conditions.

公开(公告)号：US20200239479A1

公开(公告)日：2020-07-30

申请号：US16774381

申请日：2020-01-28

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Solomon B. Ungashe ,  Stephen D. Yanofsky ,  Philip Liaw ,  Annie L. Lennek

IPC: C07D487/04 ,  A61P35/00

Abstract: Pyrazolopyrimidine RAS modulating compounds and methods of using the same are provided. The pyrazolopyrimidine compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

公开(公告)号：US12194043B2

公开(公告)日：2025-01-14

申请号：US17369203

申请日：2021-07-07

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61K31/7072 ,  A61P11/00

Abstract: The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.

公开(公告)号：US20230255971A1

公开(公告)日：2023-08-17

申请号：US17886990

申请日：2022-08-12

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Heshan Peiris ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61P1/16

CPC classification number: A61K31/519 ,  A61P1/16

Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

公开(公告)号：US20220008422A1

公开(公告)日：2022-01-13

申请号：US17369203

申请日：2021-07-07

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61K31/7072 ,  A61P11/00

Abstract: The present invention relates to compositions, formulations, and methods for treating pulmonary disorders having fibrosis as part of the underlying pathology, such as IPF and ARDS, by administration of a UPase inhibitor, with or without supplemental UR, a UR prodrug, or a UR mimetic to a subject in need thereof.

公开(公告)号：US12109222B2

公开(公告)日：2024-10-08

申请号：US17175258

申请日：2021-02-12

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Brian D. Frenzel ,  Philip Liaw

IPC: A61K31/7072 ,  A61K31/519 ,  A61K45/06 ,  A61P1/04

CPC classification number: A61K31/7072 ,  A61K31/519 ,  A61K45/06 ,  A61P1/04

Abstract: Methods for treating a subject for mucositis are provided. Aspects of the methods include administering an effective amount of a cancer therapy toxicity-reducing adjuvant in combination with uridine or a prodrug thereof to the subject. In certain embodiments, the cancer therapy toxicity-reducing adjuvant is a 2,2′-anhydropyrimidine, or a derivative thereof. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of different cancer therapy applications.

公开(公告)号：US20240091228A1

公开(公告)日：2024-03-21

申请号：US18241501

申请日：2023-09-01

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61P11/00

CPC classification number: A61K31/519 ,  A61P11/00

Abstract: The present invention relates to compositions, formulations, and methods for treating drug-induced ILF/IPF disorders by administration of a UPase inhibitor, with or without supplemental uridine, a uridine prodrug or a uridine mimetic to a subject in need thereof. Candidate drugs for the treatment include bleomycin and analogs, methotrexate and analogs, and amiodarone and analogs.

公开(公告)号：US11446303B2

公开(公告)日：2022-09-20

申请号：US16904262

申请日：2020-06-17

Applicant: Tosk, Inc.

Inventor： William A. Garland ,  Heshan Peiris ,  Philip Liaw ,  Brian D. Frenzel

IPC: A61K31/519 ,  A61P1/16

Abstract: Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and/or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

公开(公告)号：US11945803B2

公开(公告)日：2024-04-02

申请号：US17260711

申请日：2019-08-06

Applicant: Tosk, Inc.

Inventor： Annie L. Lennek ,  Stephen D. Yanofsky ,  Brian D. Frenzel ,  Solomon B. Ungashe ,  William A. Garland ,  Philip Liaw

IPC: C07D403/14 ,  C07D413/12

CPC classification number: C07D403/14 ,  C07D413/12

Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

公开(公告)号：US20220227740A1

公开(公告)日：2022-07-21

申请号：US17439989

申请日：2020-04-13

Applicant: Tosk, Inc.

Inventor： Solomon B. Ungashe ,  William A. Garland ,  Stephen D. Yanofsky ,  Brian D. Frenzel ,  Philip Liaw ,  Annie L. Lennek

IPC: C07D405/14 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04

Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.